Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484958 | 0.88 | MEN1 (0.42) | NPY5RPRKDCKDM4EMEN1KMT2A | |
| SCHEMBL5494681 | 0.86 | MEN1 (0.48) | NPY5RPRKDCKDM4EMEN1KMT2A | |
| SCHEMBL5491074 | 0.86 | MEN1 (0.57) | NPY5RCYP3A4MEN1KMT2AENPP1 | |
| Hydrochloric Acid SCHEMBL5485971 | 0.85 | ENPP1 (0.43) | MAOBHRH3MAOACYP3A4PRKDC | |
| Hydrochloric Acid SCHEMBL5485968 | 0.85 | ENPP1 (0.43) | MAOBHRH3MAOACYP3A4PRKDC | |
| Hydrochloric Acid SCHEMBL5493398 | 0.85 | MEN1 (0.50) | NPY5RPRKDCKDM4EMEN1KMT2A | |
| SCHEMBL5486775 | 0.83 | PDE3B (0.43) | MAOBHRH3MAOACYP3A4PRKDC | |
| SCHEMBL5486776 | 0.83 | PDE3B (0.43) | MAOBHRH3MAOACYP3A4PRKDC | |
| SCHEMBL5036075 | 0.83 | MAOB (0.47) | MAOBHRH3MAOACYP3A4PRKDC | |
| SCHEMBL5035944 | 0.82 | HRH3 (0.48) | MAOBHRH3MAOACYP3A4PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205309-B2 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20040029901-A1 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-12 | — | — | US | claimed |
| US-7205309-B2 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040029901-A1 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029901-A1 | Quinazoline derivatives | GPR119, NQO2, CYP7A1 | MAOB 910/4885HRH3 1196/4885NPY5R 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.